238 related articles for article (PubMed ID: 31570447)
21. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
Sehgal A; Whiteside TL; Boyiadzis M
Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
[TBL] [Abstract][Full Text] [Related]
22. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
23. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
[TBL] [Abstract][Full Text] [Related]
24. PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.
Ács B; Madaras L; Tőkés AM; Kovács AK; Kovács E; Ozsvári-Vidákovich M; Karászi Á; Birtalan E; Dank M; Szász AM; Kulka J
Breast; 2017 Oct; 35():69-77. PubMed ID: 28651116
[TBL] [Abstract][Full Text] [Related]
25. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
26. Herpesvirus Entry Mediator as an Immune Checkpoint Target and a Potential Prognostic Biomarker in Myeloid and Lymphoid Leukemia.
Basingab FS; Alzahrani RA; Alrofaidi AA; Barefah AS; Hammad RM; Alahdal HM; Alrahimi JS; Zaher KA; Algiraigri AH; El-Daly MM; Alkarim SA; Aldahlawi AM
Biomolecules; 2024 Apr; 14(5):. PubMed ID: 38785930
[TBL] [Abstract][Full Text] [Related]
27. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
28. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia.
Perko R; Kang G; Sunkara A; Leung W; Thomas PG; Dallas MH
Biol Blood Marrow Transplant; 2015 Jan; 21(1):130-6. PubMed ID: 25445640
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of aberrant PD-1 expression for acute leukemia prognosis.
Ruan Y; Wang J; Zhang Q; Wang H; Li C; Xu X; Zhai Z
Eur J Med Res; 2023 Sep; 28(1):383. PubMed ID: 37759316
[TBL] [Abstract][Full Text] [Related]
30. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
[TBL] [Abstract][Full Text] [Related]
31. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
[TBL] [Abstract][Full Text] [Related]
32. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
33. Expression of PD1 and BTLA on the CD8
Bao Y; Mo JF; Wu JY; Cao CX
Chin Med Sci J; 2019 Nov; 34(4):248-255. PubMed ID: 33906710
[No Abstract] [Full Text] [Related]
34. Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia.
Mansour A; Elkhodary T; Darwish A; Mabed M
Leuk Lymphoma; 2014 Sep; 55(9):2120-4. PubMed ID: 24283754
[TBL] [Abstract][Full Text] [Related]
35. Checkpoint inhibition in pediatric hematologic malignancies.
Davis KL; Agarwal AM; Verma AR
Pediatr Hematol Oncol; 2017; 34(6-7):379-394. PubMed ID: 29190182
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
Takeuchi M; Miyoshi H; Nakashima K; Kawamoto K; Yamada K; Yanagida E; Muta H; Moritsubo M; Umeno T; Suzuki T; Seto M; Ohshima K
Ann Hematol; 2020 May; 99(5):1093-1098. PubMed ID: 32157421
[TBL] [Abstract][Full Text] [Related]
37. Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.
Tracy SI; Venkatesh H; Hekim C; Heltemes-Harris LM; Knutson TP; Bachanova V; Farrar MA
Blood; 2022 Jul; 140(4):335-348. PubMed ID: 35275990
[TBL] [Abstract][Full Text] [Related]
38. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
40. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]